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METHODS & TECHNIQUES
Protein interference applications in cellular and developmental
biology using DARPins that recognize GFP and mCherry
Michael Brauchle1,2,*, Simon Hansen3,*, Emmanuel Caussinus1,`, Anna Lenard1,`, Amanda Ochoa-Espinosa1,`,
Oliver Scholz3, Simon G. Sprecher2, Andreas Plu¨ckthun3,§ and Markus Affolter1,§
ABSTRACT
Protein–protein interactions are crucial for cellular homeostasis and
play important roles in the dynamic execution of biological
processes. While antibodies represent a well-established tool to
study protein interactions of extracellular domains and secreted
proteins, as well as in fixed and permeabilized cells, they usually
cannot be functionally expressed in the cytoplasm of living cells.
Non-immunoglobulin protein-binding scaffolds have been identified
that also function intracellularly and are now being engineered for
synthetic biology applications. Here we used the Designed Ankyrin
Repeat Protein (DARPin) scaffold to generate binders to fluorescent
proteins and used them to modify biological systems directly at the
protein level. DARPins binding to GFP or mCherry were selected by
ribosome display. For GFP, binders with KD as low as 160 pM were
obtained, while for mCherry the best affinity was 6 nM. We then
verified in cell culture their specific binding in a complex cellular
environment and found an affinity cut-off in the mid-nanomolar
region, above which binding is no longer detectable in the cell. Next,
their binding properties were employed to change the localization of
the respective fluorescent proteins within cells. Finally, we
performed experiments in Drosophila melanogaster and Danio
rerio and utilized these DARPins to either degrade or delocalize
fluorescently tagged fusion proteins in developing organisms, and to
phenocopy loss-of-function mutations. Specific protein binders can
thus be selected in vitro and used to reprogram developmental
systems in vivo directly at the protein level, thereby bypassing some
limitations of approaches that function at the DNA or the RNA level.
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INTRODUCTION
Protein–protein interactions are at the basis of virtually all
biological phenomena. Therefore, it is of high importance to
discover which proteins interact, to understand where and how
they form interfaces in the cell and to discover what the
biological consequences of their interactions are. Experimental
and computational approaches are now underway attempting to
map phenotype to genotype down to the residue level (Ryan et al.,
2013), but achieving this goal lies still far in the future.
Ultimately, protein interactions that are well understood cannot
only be inhibited but also used to engineer desired cellular
outcomes. Such advances have impact in diverse areas of basic
biological research and possibly also in future medical
applications.
To study individual protein–protein interactions, it is desirable
to specifically manipulate an interaction of interest. To analyze a
single protein–protein interaction a very specific approach has to
be chosen, since the removal of a protein would result in the
cumulative loss of all interactions of that protein. Provided that
the protein–protein interaction site is known, this can be achieved
by mutating the required amino acid(s), however, this information
is rarely available. Another possibility is to use antibodies that
can mask a specific epitope on the surface of an extracellular or
secreted protein, or, after cell permeabilization, also intracellular
proteins. Indeed, it has been shown that an antibody can inhibit
only a single function of a multifunctional protein containing an
extracellular domain, e.g. by Ingvarsen et al. (Ingvarsen et al.,
2013). However, this approach cannot be used within a living
cell, since most antibodies cannot be functionally expressed, as
they contain disulfides and will generally not fold in the reducing
cytoplasm. On the other hand, an engineered protein binder, e.g. a
peptide, small molecule or an exogenous protein can successfully
interfere with a specific protein–protein interaction also intracellularly.
For example, small molecule drugs often interact highly
specifically with a particular binding pocket of a protein in order
to modify a biological outcome otherwise leading to a disease.
However, no specific small molecule is available for the great
majority of targets or specificity cannot be ascertained. This
situation is even much more dismal for proteins of model
organisms, since almost all small molecules are being developed
for human targets.
Over the past decade, a number of non-antibody scaffolds have
been engineered to identify protein binders that can be used to
manipulate biological systems (Binz and Plu¨ckthun, 2005).
Designed Ankyrin Repeat Protein based binders (DARPins) are
one example of such a designed scaffold (Boersma and Plu¨ckthun,
2011). They were created through consensus analysis of natural
ankyrin repeat proteins and are characterized by low molecular
weights (ca. 14–18 kDa), high biophysical stability and efficient
production in E. coli even when the binding surface is randomized
(Binz et al., 2003). Such surface-randomized libraries allow the
selection of binders with picomolar to low nanomolar affinities
(Binz et al., 2003; Zahnd et al., 2007) and converting the selection
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technology to high throughput has generated binders for over 170
targets up to now (J. Schaefer and A.P., unpublished). DARPins have
been used for many intracellular applications, e.g. as real-time, real-
space fluorescent sensors of the conformation of a kinase (Kummer
et al., 2012), as very selective intracellular inhibitors of particular
kinases (Parizek et al., 2012), caspases (Schweizer et al., 2007) and
other proteases (Amstutz et al., 2005; Kawe et al., 2006), or as
tubulin polymerization inhibitor (Pecqueur et al., 2012). A DARPin
against VEGF-A has been shown to reduce neovascularization in
different animal models (Stahl et al., 2013) and in human patients
(Souied et al., 2014) and will soon be entering phase III clinical
trials.
Besides generating binders to the target itself, it is possible to
select binders to a partner that is frequently used as a fusion
protein in research, e.g. GFP. A single-domain antibody of 117
amino acids has been identified from immunized llamas (also
called nanobody VHH4), which binds with high affinity and
selectivity to GFP (Rothbauer et al., 2008). It has been used to
purify GFP-tagged proteins (Rothbauer et al., 2008), interfere
with or mis-localize GFP fusion proteins (Schornack et al., 2009),
degrade fusion proteins (Caussinus et al., 2012) or to help
visualize protein–protein interactions in living cells (Herce et al.,
2013). Subsequently, additional GFP-binding nanobodies with
alternative epitopes have been described (Kirchhofer et al., 2010),
which can be combined to assemble protein complexes (Tang
et al., 2013).
Despite the prevalent use of fluorescent proteins in different
areas of basic research, no protein binders other than to GFP are
currently available that can be used to engineer and manipulate
cellular systems containing such fluorescent proteins. Clearly,
additional protein binders against GFP and especially other
fluorescent proteins would increase the possibilities for
combinatorial manipulations. Therefore, we set out to generate
a set of high-affinity and highly specific DARPins binding to the
fluorescent proteins GFP and mCherry. We show that the
identified binders recognize their target in vitro and in living
cells with high selectivity and affinity. We then use these
genetically encoded DARPins to modify protein function in
different animal models, either by degrading or re-localizing
fluorescent proteins in developing organisms. Together these
results highlight the DARPin technology as an efficient platform
to generate specific protein binders which open up new
possibilities for functional analyses of fluorescent proteins in
different cellular and developmental systems.
RESULTS
Selection and in vitro characterization of GFP- and mCherry-
binding DARPins
To identify DARPins that specifically bind to fluorescent proteins
we performed four rounds of ribosome display using the N2C and
N3C libraries (Binz et al., 2003) with GFP and mCherry as target
proteins, respectively. For GFP as a target, the enriched pool of
DNA was subcloned into an E. coli expression vector and crude
extracts of 192 single clones were screened against GFP by
ELISA. In the GFP binder selection, approximately 70% of the
single clones from the N2C (see Materials and Methods) library
were hits that resulted in a high, GFP-specific signal, and around
50% of the clones from the N3C library pool scored as positive.
All positive clones were also tested for binding to superfolder
GFP (sfGFP), an engineered variant with 10 amino acid
differences, most of which are on the surface (Pe´delacq et al.,
2006) (supplementary material Fig. S1). As this version was not
used during the selection, only a fraction of binders initially
selected against GFP also showed binding to sfGFP, as expected
from the high specificity of DARPins. No clone from the N2C
library was found to bind sfGFP, but 13 clones of the N3C library
did bind to sfGFP as well (data not shown). To examine binding
against several GFP variants in more detail, six clones out of the
13 sfGFP binders were chosen for further analysis (3G61,
3G86.1, 3G86.32, 3G124, 3G146 and 3G168; for an explanation
of the nomenclature, see Materials and Methods).
Single clones from the selections against mCherry showed
fewer positive hits, ca. 10–15% from the N2C and N3C pools,
respectively. Five clones from these positive hits were chosen for
further analysis (2m22, 2m74, 2m151, 2m172 and 3m160). We
then assessed the specificity, oligomeric state, target affinity and
epitope overlap of the selected DARPins after performing a single
purification step using immobilized metal affinity chromatography
(IMAC) (supplementary material Fig. S2).
First, the in vitro specificity of the selected DARPins was
tested using an ELISA comparing the binding of all selected
DARPins, together with control DARPins, to GFP, sfGFP, eGFP,
eYFP, mCherry and mRuby2, respectively. Reassuringly, all
DARPins showed specific binding to their cognate target (and
its close homologs) exclusively (Fig. 1A); no cross-reactivity
between GFP- and mCherry-selected DARPins was observed. All
anti-GFP DARPins also bound the closely related sfGFP, eGFP
and eYFP (Fig. 1A), although sometimes with lower (e.g. 3G146
binding to sfGFP) binding signals. The anti-mCherry DARPins
exclusively bound mCherry (Fig. 1A). No DARPin significantly
bound mRuby2. Control DARPins off7, selected against maltose
binding protein (Binz et al., 2004), and E 3_5, an unselected
library member (Binz et al., 2003; Kohl et al., 2003), showed
practically no background binding against GFP, sfGFP, eGFP,
eYFP, mCherry or mRuby2 and none of the DARPins showed
binding above background levels in control wells without coated
target (Fig. 1A).
Second, the oligomeric state of all selected DARPins was
assessed by analytical size exclusion chromatography (SEC). All
but the anti-mCherry DARPin 2m22 showed single elution peaks,
in some cases with very small secondary peaks (Fig. 1B). The
major DARPin peaks generally eluted with a slight retardation,
giving a slightly lower apparent MW than expected (Table 1),
calculated using a protein standard consisting of four globular
proteins. This indicates that they are exclusively monomeric and
compactly folded, but may have a slight interaction with the size
exclusion column. Anti-mCherry DARPin 2m22 showed two
elution peaks, a main peak at an apparent MW of 9.0 kDa
corresponding to the monomeric fraction which is retarded on the
column and a minor peak at 32.3 kDa with about half the height,
probably corresponding to a dimeric fraction (Fig. 1B; Table 1).
Importantly, upon incubation of DARPin 2m22 with an
equimolar amount of its cognate target mCherry, all of the
mCherry shifts to a single peak of higher molecular weight in
SEC, indicating that also the dimeric fraction of 2m22 is
incorporated into a 1:1 complex with mCherry (supplementary
material Fig. S3).
Third, we measured the affinity of the DARPins for their
target by both fluorescence anisotropy (FA) (Fig. 1C; Table 1)
and surface plasmon resonance (SPR) (Fig. 1D; Table 1;
supplementary material Fig. S4). FA is a very useful method
for accurate determination of affinities down to approximately
5 nM, such as those obtained with the non-cognate target sfGFP
(Table 1). However, it is not sensitive enough to determine
METHODS & TECHNIQUES Biology Open (2014) 3, 1252–1261 doi:10.1242/bio.201410041
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picomolar affinities, since the interaction partners need to be
diluted below the dissociation constants (KD), resulting in signals
which are too weak for precise measurements. Thus, the KD of
DARPins 3G61, 3G86.1, 3G86.32, 3G124 and 3G168 were
determined with SPR (Fig. 1D; supplementary material Fig. S4),
with the best binder, 3G86.32, yielding a KD of 160 pM for its
cognate target GFP (Table 1).
In addition, GFP binder 3G61 was measured with both FA and
SPR, with the aim to be able to compare the two methods with
each other. When measured in the same buffer, we could
ascertain that the methods give similar KD values, even though
the FA-measured value could not be fitted exactly, as explained
above (Table 1). During these measurements, we observed that
the KD for this particular DARPin appears to depend on buffer
composition (PBS containing either 0.03% BSA (standard buffer
for FA) or 0.005% of detergent). Three different detergents,
Tween-20, Triton X-100 and decyl-maltoside (DM), were tested
and they all increased the affinity of 3G61 to GFP, although to
different extents (supplementary material Fig. S5A). In the SPR
experiments PBS with 0.005% Tween-20 was used. An increase
of affinity induced by detergent was also observed for 3G146 but
not for any of the other anti-GFP DARPins (data not shown); the
Fig. 1. Specificity, oligomeric state and affinity of
anti-GFP and anti-mCherry DARPins. (A) ELISA
experiments show a high specificity of selected DARPins
towards their cognate target and closely related proteins.
Off7 is a control DARPin binding to maltose binding
protein (MBP), E 3_5 is an unselected DARPin. All bars
represent mean values of duplicates, error bars represent
standard deviations. (B) Analysis of the oligomeric state
by SEC shows that most DARPins are predominantly
monomeric. Due to low extinction coefficients at 280 nm
for the chromatograms of 2m22 and 2m74 the absorption
at 230 nm is shown. Arrows indicate the elution
volumes of the molecular weight standard with the
respective MWs. (C) Example of FA assays of different
DARPins binding to sfGFP. The solid line indicates a fit to
a 1:1 binding model. Extracted KDs for all DARPins can
be found in Table 1. (D) Example of a kinetic titration
SPR experiment of 3G124 binding to GFP. The
concentrations of the five DARPin injections are indicated
in the graph. Fit to a global 1:1 kinetic titration binding
model is indicated in red. Extracted association and
dissociation rates and KDs for several DARPins are
summarized in Table 1; additional sensograms are
shown in supplementary material Fig. S4.
Table 1. Affinities and oligomeric states of GFP and mCherry-binding DARPins
Affinity Size exclusion chromatography
FAa Surface plasmon resonanceb
Theoretical MW
(kDa)
Apparent MW
(kDa)c
Oligomeric
stateDARPin Target KD 6 S.D. (nM) ka (M
21 s21 ) kd (s
21) KD (nM)
2m22 mCherry 6.661.3 n.d. n.d. n.d. 14.99 32.3/9.0d Dimer/Monomer
3m160 mCherry 46067 n.d. n.d. n.d. 18.57 13.1 Monomer
2m151 mCherry 56006670 n.d. n.d. n.d. 15.02 6.2 Monomer
2m74 mCherry 790061400 n.d. n.d. n.d. 15.00 6.5 Monomer
2m172 mCherry 15,10062500 n.d. n.d. n.d. 14.92 8.3 Monomer
3G61 GFP 76621/,5b 0.7616106 7.9761024 1.1 18.34 13.6 Monomer
sfGFP 96616 n.d. n.d. n.d.
3G86.1 GFP ,5 1.176106 3.6961024 0.32 18.43 12.6 Monomer
sfGFP 2962.0 n.d. n.d. n.d.
3G86.32 GFP ,5 1.376106 2.261024 0.16 18.43 16.7 Monomer
sfGFP 5.360.7 n.d. n.d. n.d.
3G124 GFP ,5 0.6336106 2.2861024 0.36 18.33 13.1 Monomer
sfGFP 2260.3 n.d. n.d. n.d.
3G146 GFP 15668 n.d. n.d. n.d. 18.59 8.3 Monomer
sfGFP 6866200 n.d. n.d. n.d.
3G168 GFP ,5 1.256106 3.3961024 0.27 18.46 12.0 Monomer
sfGFP 1662.3 n.d. n.d. n.d.
n.d.: not determined.
aFluorescence anisotropy, unless stated otherwise performed in PBS with 0.03% BSA.
bPerformed in PBS with 0.005% Tween-20.
cCalculated from a molecular weight standard, see Materials and Methods.
dApparent MWs for minor and major peaks, respectively.
METHODS & TECHNIQUES Biology Open (2014) 3, 1252–1261 doi:10.1242/bio.201410041
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exact molecular cause will require further investigations. We
must of course expect that the intracellular situation will be
reflected by the absence of detergent-like molecules.
The five selected mCherry binding DARPins had lower
affinities, only DARPin 2m22 had a KD in the low nanomolar
range; 3m160 had an intermediate affinity with a KD of about
460 nM, while the other mCherry binders had affinities in the mM
range (Table 1).
Finally, we performed epitope binning experiments to determine
whether the selected DARPins bind to overlapping or to different
epitopes on their respective target protein. For the GFP binders,
SPR as well as FA measurements were used. In the SPR
experiments, two consecutive injections of different anti-GFP
DARPins at concentrations saturating all immobilized ligand were
made. At the time of the second injection, a large amount of
the previously injected anti-GFP DARPin was still bound to the
GFP-coated surface. None of the second injections resulted in a
signal significantly above the plateau reached with the first
injection, suggesting that all anti-GFP DARPins bind to
overlapping GFP epitopes (supplementary material Fig. S6). This
result was corroborated by the FA experiments, in which GFP was
incubated either with no, with one or with two DARPins. Incubation
with one anti-GFP DARPin resulted in a significant rise of the
anisotropy compared to GFP alone. Addition of a second anti-GFP
DARPin, however, did not increase the anisotropy further in any
case tested (supplementary material Fig. S7). Epitope binning using
FA was also attempted for the mCherry binders, but the results were
inconclusive; this is likely due to the different MWs of the anti-
mCherry DARPins resulting from the use of different libraries and/
or the significantly different KD values found among the mCherry
binders. In conclusion, we identified here mainly monomeric
DARPin binders for GFP and mCherry that specifically bind to their
target in vitro with high affinities (Fig. 1; Table 1).
Anti-GFP and anti-mCherry DARPins bind the respective
fluorescent protein in cultured cells
Next we wanted to test the intracellular expression and binding
behavior of the identified DARPins in a complex cellular
environment. For this purpose, we fused the anti-GFP DARPins
to yet another orthogonal fluorescent protein, mRuby2, to which
they have no affinity as verified by ELISA (Fig. 1A), which
allowed us to directly visualize the subcellular location of the
DARPin fusion proteins within the cell (Fig. 2). Since the DARPins
fold well even as fusion proteins to fluorescent proteins, unlike
antibody scFv fragments (Griep et al., 1999), such DARPin-GFP
fusion proteins have been routinely used, e.g. when testing
DARPins for binding to surface receptors by FACS (Stefan et al.,
2011). Upon transfection of individual DARPin-mRuby2 (or -GFP)
Fig. 2. Binding of anti-GFP-DARPin-Ruby2 fusions to GFP in HeLa
cells. Shown are HeLa cells transiently overexpressing a DARPin-mRuby2
fusion protein (A–G) (H is an mRuby2-nanobody fusion) together with a GFP
version tethered to the plasma membrane (GFP-CVIM, A9–H9). Overlap of
fluorescent signal indicates binding of the respective anti-GFP-DARPin-
mRuby2 fusion to GFP-CVIM, indicated by the yellow fluorescent signal at
the plasma membrane. (A–A0) As expected, the anti-mCherry DARPin 2m22-
mRuby2 fusion protein, which does not recognize GFP, is not recruited to the
plasma membrane. (B–B0) 3G86.32-mRuby2, (C–C0) 3G168-mRuby2,
(D–D0) 3G124-mRuby2 as well as (E–E0) 3G86.1-mRuby2 fusion proteins
localize to the plasma membrane where they interact with GFP-CVIM. On the
other hand, low affinity (F–F0) 3G61-mRuby2 and (G–G0) 3G146-mRuby2
fusion proteins localize to the cytoplasm and nucleus, indicating that they
cannot interact sufficiently with GFP-CVIM anchored in the plasma
membrane. (H–H0) Positive control mRuby2-VHH-GFP4 fusion protein
localizes to the plasma membrane. Unprimed letters, mRuby2 channel;
primed letters, GFP channel; double primed letters, overlay. Scale bars are
20 mm.
METHODS & TECHNIQUES Biology Open (2014) 3, 1252–1261 doi:10.1242/bio.201410041
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fusion constructs into HeLa cells, we observed a diffuse
cytoplasmic and enriched nuclear fluorescent signal (for an
example, see Fig. 2A). This localization was the same as for the
respective fluorescent protein itself without a fused DARPin
(supplementary material Fig. S8A).
We then co-expressed these DARPin-mRuby2 fusions with
membrane-bound versions of the fluorescent proteins they
recognize; for this purpose, a ‘‘CaaX’’ motif (Kitten and Nigg,
1991), here in the form of CVIM, was added to the C-termini of
GFP or mCherry, which leads to farnesylation of the fluorescent
proteins (Fig. 2A9). We predicted that the DARPin-fusions would
change their subcellular location upon binding to their respective
fluorescent target, which is anchored in the plasma membrane.
We overexpressed six anti-GFP DARPins fused to mRuby2
and assessed their localization upon co-expression with GFP-
CVIM (Fig. 2B–H). Indeed, 3G86.32-mRuby2 (Fig. 2B), 3G168-
mRuby2 (Fig. 2C), 3G124-mRuby2 (Fig. 2D) and 3G86.1-mRuby2
(Fig. 2E) re-localized to the plasma membrane in the presence of
GFP-CVIM, indicating a strong intracellular interaction between
these anti-GFP DARPins and GFP-CVIM, consistent with their
very high affinity (Table 1). On the other hand, 3G61-mRuby2
(Fig. 2F) and 3G146-mRuby2 (Fig. 2G) failed to re-localize to the
plasma membrane. A possible explanation is that their mid-
nanomolar affinity as determined by FA (Table 1) is not strong
enough to support an intracellular re-localization. To exclude
possible steric interference of the plasma membrane with
formation of the DARPin-GFP complex (as the CVIM anchor
might bring the GFP epitope too close to the membrane), we
reversed the experiment by anchoring the tight binding DARPin
3G86.32-mRuby2-CVIM to the plasma membrane and tested if it
can recruit cytoplasmic GFP. Indeed, GFP was recruited to the
plasma membrane by this DARPin (supplementary material Fig.
S8B9), while the lower affinity DARPins, 3G61-mRuby2-CVIM
(supplementary material Fig. S8C9) and 3G146-mRuby2-CVIM
(supplementary material Fig. S8D9), did not maintain GFP at the
plasma membrane, again suggesting that the insufficient affinity is
the cause of not allowing a prolonged protein–protein interaction in
a cellular environment.
We then repeated this experimental approach to validate a
subset of our anti-mCherry DARPins (Fig. 3). Four anti-mCherry
DARPins were fused to GFP (which they do not recognize,
Fig. 1A) and their localization was tested upon co-expression
with a membrane-bound form of mCherry, mCherry-CVIM
Fig. 3. Binding of anti-mCherry-Darpin-GFP fusions to mCherry in HeLa
cells. Shown are HeLa cells transiently overexpressing GFP (A) or anti-
mCherry-GFP fusion proteins (B–E) together with a mCherry version
tethered to the plasma membrane (mCherry-CVIM, A9–E9). Overlap of
fluorescent signal indicates binding of the respective anti-mCherry-DARPin-
GFP fusion to mCherry-CVIM, indicated by the yellow fluorescent signal at
the plasma membrane. (A–A0) As expected, the untethered GFP control
does not change its subcellular localization upon co-expression with
mCherry-CVIM and remains cytoplasmic and nuclear. (B–B0) 2m22-GFP
re-localizes to the plasma membrane where it binds to mCherry-CVIM.
(C–C0) The 3m160-GFP fusion protein results in some fluorescent signal at
the plasma membrane indicating the weaker affinity to mCherry-CVIM.
(D–D0) 2m151-GFP and (E–E0) 2m74-GFP fusion proteins are not
significantly recruited to the plasma because of their only micromolar affinity.
Unprimed letters, GFP channel; primed letters, mCherry channel; double
primed letters, overlay. Scale bars are 20 mm.
Fig. 4. Expression of a Slmb-anti-GFP-DARPin fusion in Drosophila
embryos degrades eYFP. (A) Shown is an embryo with the following
genotype: H2A-eYFP; en-GAL4, UAS-mCherryNLS; UAS-Slmb-3G86.32.
Nuclei that express the Slmb-anti-GFP-DARPin in the engrailed pattern are
also expressing unfused mCherry. It can be seen that red cells lost the eYFP
signal. (B–B0) Close-up of another embryo showing the channel-specific
signal of eYFP (B), mCherry (B9) and the overlay (B0). Note again that cells
expressing mCherry have strongly reduced H2A-eYFP signal, indicating
efficient eYFP degradation due to the expression of a Slmb-anti-GFP-Darpin.
Scale bars are 20 mm.
METHODS & TECHNIQUES Biology Open (2014) 3, 1252–1261 doi:10.1242/bio.201410041
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(Fig. 3A9). We observed that 2m22-GFP (Fig. 3B) and 3m160-
GFP (Fig. 3C), which have nanomolar affinities, displayed a
membrane-associated localization, indicative of binding to
mCherry-CVIM, while 2m151-GFP (Fig. 3D) and 2m74-GFP
(Fig. 3E) with micromolar affinities did not change their
localization. Furthermore, we also verified that the anti-GFP
and anti-mCherry DARPins as Ruby2-fusion proteins only bound
to their cognate fluorescent protein target; this was indeed the
case as the anti-mCherry-Ruby2 fusion does not bind GFP
(Fig. 2A and data not shown).
As a further control, we tested the anti-GFP-nanobody VHH-
GFP4 (Rothbauer et al., 2008), fused to mRuby2, and co-expressed
it with a GFP-CVIM (Fig. 2H). Indeed, the mRuby2-VHH-GFP4
fusion protein localized to the plasma membrane (Fig. 2H), co-
localizing with GFP-CVIM in that location (Fig. 2H9,H0), hereby
validating this approach.
Taken together, we found that in a cellular system, only those
DARPins which show at least mid-nanomolar affinity in PBS
bind to their target. The affinity cut-off between GFP binders and
mCherry binders is not identical, since geometric factors may
well play a role. In summary, we identified four anti-GFP
DARPins (3G86.32, 3G168, 3G124 and 3G86.1), as well as two
anti-mCherry DARPins (2m22 and 3m160), which specifically
bind to their respective fluorescent protein both in vitro and in
cultured cells.
Anti-GFP and anti-mCherry DARPins can be functionalized for
in vivo experiments in Drosophila and zebrafish
These successful cell culture experiments encouraged us to test
these novel DARPin reagents in vivo in multicellular organisms
and to evaluate whether the expression of such DARPin fusion
constructs would have any deleterious effects in a living organism
in the absence of the target fluorescent protein. It has previously
been shown that a fusion of the VHH-GFP4 nanobody with a F-
box protein can lead to the degradation of GFP-tagged proteins
(Caussinus et al., 2012). Using the same experimental approach,
we fused the anti-GFP DARPin 3G86.32 to the identical
Drosophila Slmb F-box domain. We generated transgenic flies
expressing the Slmb-3G86.32 fusion protein under a UAS
promoter, and drove its expression using the engrailed (en)-
Gal4 driver; at the same time we labelled these cells with
mCherry using the same driver. This is expected to lead to an
expression of both the DARPin-F-box fusion protein and the
(unfused) mCherry in an engrailed pattern. We then crossed these
flies with a fly strain, in which all cell nuclei express a histone
fusion, H2A-eYFP (note that eYFP is also recognized by the anti-
GFP DARPins, as shown by ELISA (Fig. 1A)). At the
developmental time when the en driver becomes active in a
stripe-like manner at the posterior part of each body parasegment,
the Slmb-3G86.32 fusion protein is expressed in these stripes.
The cells within these stripes loose H2A-eYFP (Fig. 4),
indicating that the anti-GFP DARPin-F-box fusion protein
targeted H2A-eYFP for degradation. These cells can be
recognized by their expression of the unfused mCherry. As a
control, we also expressed the Slmb-3G86.32 fusion protein
under the control of the ubiquitous driver tub-Gal4 in a wild-type
fly not expressing any GFP fusion protein (data not shown). Such
transgenic flies were viable and developed normally, indicating
Fig. 5. Tissue specific expression of a Slmb-anti-GFP-DARPin fusion in
Drosophila phenocopies a non-muscle myosin II mutant phenotype.
(A) Shown is an embryo with the following genotype: sqhAX3; sqhSqh::GFP.
The arrow points to the normal dorsal closure. (B) Shown is an embryo with
the following genotype: sqhAX3/Y; sqhSqh::GFP/Gal4; NSlmb-3G86.32/+.
The dotted line outlines the ‘‘dorsal open’’ phenotype exposing the
amnioserosa. Scale bars are 20 mm.
Fig. 6. anti-GFP-DARPin fusion proteins can relocalize fluorescent
fusion proteins in D. rerio embryos. (A,B) 3G86.2-mRuby2 binds GFP in
living zebrafish embryos. (A) Control embryo showing the localization of
3G86.32-mRuby2 in two adjacent skin cells. (B–B0) In a zebrafish embryo
co-expressing membrane-bound GFP-CVIM (B), 3G86.32-mRuby2 now
localizes to the plasma membrane (B9) and shows a virtually complete
co-localization with GFP-CVIM (B0). (C,D) membrane-anchored 3G86.32-
mRuby2-CVIM recruits GFP-rab5c in living zebrafish embryos. (C) Control
embryo showing the localization of GFP-rab5c in two adjacent skin cells.
(D–D0) In a zebrafish embryo co-expressing membrane-bound 3G86.32-
mRuby2-CVIM (D9), GFP-Rab5C also localizes to the plasma membrane
(D) and shows a virtually complete co-localization with 3G86.32-mRuby2-
CVIM (D0). Scale bars are 20 mm.
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that the presence of the Slmb-3G86.32 fusion protein does not
lead to the degradation of any other essential protein, further
indicating the high degree of specificity of the anti-GFP DARPin
to its respective GFP or eYFP target.
Next, we attempted to degrade an endogenously GFP-tagged
protein in Drosophila in order to assess whether we were able to
phenocopy the mutant phenotype of the gene of interest. For this
purpose, we used a fly line expressing Spaghetti squash (Sqh) (a
subunit of the non-muscle myosin II complex) as a GFP fusion
protein under the control of its own promoter, hereafter called
sqhSqh::GFP, thereby rescuing the sqh mutant (Fig. 5A) (Royou
et al., 2004; also see Caussinus et al., 2012). In such embryos, we
expressed the F-Box anti-GFP DARPin fusion protein, Slmb-
3G86.32, using an amnioserosa-specific GAL4 driver. These flies
exhibited a clear phenotype where the lateral epidermis could not
close at the dorsal side, similar to what is observed in strong sqh
alleles (Young et al., 1993), indicating that the sqhSqh::GFP
protein was successfully degraded in the amnioserosa (Fig. 5B).
Therefore, mutant phenotypes can be phenocopied using DARPin
based reagents.
Since zebrafish is an interesting model system for vertebrate
development and for live imaging analyses, we also wanted to
test an anti-GFP DARPin in living zebrafish embryos. Again, we
fused the anti-GFP DARPin 3G86.32 to mRuby2 in order to be
able to follow its intracellular localization upon expression, and
injected the plasmid encoding this fusion protein into fertilized
zebrafish eggs. As expected, we observed mosaic expression
(Stuart et al., 1990), and 3G86.32-mRuby2 was detected in
various cell types, including skin cells, where we again observed
a diffuse cytoplasmic localization together with a nuclear
enrichment (Fig. 6A). We next co-injected the 3G86.32-
mRuby2 encoding plasmid with a second plasmid encoding
GFP-CVIM. Upon co-expression, a dramatic re-localization of
3G86.32-mRuby2 was observed: in skin cells labelled with
membrane bound GFP-CVIM, 3G86.32-mRuby2 also localized to
the plasma membrane (Fig. 6B–B0). Comparing the different
fluorescent channels with each other revealed that the co-
localization was virtually complete upon GFP-CVIM expression
(Fig. 6B0).
We then wanted to know whether the expression of a localized
anti-GFP DARPin can be used to re-localize a functional GFP
fusion protein. To test this, we chose GFP-Rab5c, which is
normally distributed in a dotted pattern reminiscent of early
endosomes (Clark et al., 2011), as this protein, which is involved
in vesicle docking and fusion, is attached to the endosomal
membrane from the cytoplasmic side. Transient expression of this
fusion protein resulted in mosaic zebrafish skin cells with the
expected fluorescent distribution of highly dynamic punctate
staining in the cytoplasm (Fig. 6C). Upon co-expression of GFP-
Rab5c with a membrane anchored 3G86.32-mRuby2-CVIM, we
observed that GFP-Rab5c now co-localized with the anti-GFP
DARPin to the plasma membrane (Fig. 6D–D0). This result
shows that the localization of a GFP-tagged protein in cells of a
living organism can be altered by taking advantage of a protein–
protein interaction engineered in the lab.
DISCUSSION
Here we have generated and characterized protein binders
selective for either GFP (and closely related fluorescent
proteins) or mCherry using the DARPin technology.
Importantly, the whole selection was done in vitro and
therefore differs from the previously identified GFP binders of
the nanobody category, which required immunization of a
camelid (Rothbauer et al., 2008; Twair et al., 2014). To our
knowledge, this is the first time that protein binders to a
fluorescent protein other than GFP have been made, now
allowing approaches using multiple fluorescent targets at the
same time. We went on to show that these binders recognize the
respective fluorescent protein in cultured cells, as well as in cells
of Drosophila and zebrafish embryos, and that the binders can be
functionalized in order to modify and control protein function.
This is possible since DARPins, which have no cysteines, express
well and fold properly in the cytoplasm of any cell. Also, their
robust architecture allows them to fold as fusions to many
proteins, including fluorescent proteins.
Four of the six GFP-binding DARPins (3G86.1, 3G86.32,
3G124 and 3G168) had the same residues at some variable
positions (supplementary material Fig. S9; Table S1); they
probably bind the same epitope, as they compete with each other
for binding and have similar binding kinetics. These four binders
possess a cysteine residue at one of the semi-variable positions,
which is not intended in the DARPin design. This residue is at the
back of the molecule (away from the binding site) where in the
original library (Binz et al., 2003) three different residues (Asn, His
or Tyr) are encoded (supplementary material Fig. S9). Indeed, in
3G124 this cysteine was exchanged with a tyrosine without
affecting its affinity (data not shown). No sign of aggregation was
observed in these proteins despite not using reducing agents in any
of the purification steps; in the reducing cytoplasm, this is not an
issue.
The structures and epitopes of 3G124 and 3G61 have been
determined by protein crystallography (Batyuk et al., manuscript
in preparation) and were shown to be different but overlapping,
thereby explaining that they compete with each other for binding.
3G61 and 3G146 showed an improved binding affinity to GFP in
detergent-containing buffers (supplementary material Fig. S5A).
This has nothing to do with an altered oligomeric state of GFP or
the DARPin through detergent addition, since 3G61 shows the
same behavior towards sfGFP (supplementary material Fig. S5B),
which is predominately monomeric in PBS (data not shown) and
less aggregation-prone (Pe´delacq et al., 2006). Both DARPins
show predominantly monomeric behavior in SEC, performed
without detergents in the buffer. We believe that 3G61 and 3G146
are to some extent adsorbed by the microtiter plates during the FA
assays, which lowers the free DARPin concentration and
therefore results in higher apparent KDs, but the molecular
details will require further investigations. None of the other
DARPins show this behavior.
The DARPins selected to bind to GFP also bind to the
closely related sfGFP, eGFP and eYFP (96, 99 and 97%
sequence identity, respectively; Fig. 1A and supplementary
material Fig. S1), albeit with reduced affinity to sfGFP
(Table 1), expanding their range of uses. Importantly, none of
the DARPins selected against GFP bind mCherry or mRuby2,
and vice-versa. This is not surprising, given that the sequences
of mCherry and mRuby2 have only 27 and 30% sequence
identity to GFP, respectively. Moreover, DARPins selected
against mCherry do not bind mRuby2, as these two proteins
share only 54% of their sequence (Fig. 1A; supplementary
material Fig. S1). As one would expect, the in vitro data
corresponded well with the observations in cell culture, that is,
that the strongest in vitro binders also bound their respective
fluorescent protein inside cells significantly better than some of
the weaker in vitro binders.
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DARPins can be generated in vitro, without using any
immunization, against any target with high affinity and
specificity (Boersma and Plu¨ckthun, 2011), thus opening up
many possibilities for targeting the cellular proteins directly, not
only via the detour of targeting an artificial fusion protein as a
‘‘recognition tag’’. The newly developed LoopDARPins
(Schilling et al., 2014) have shown that the rapid selection of
specific binders to individual family members of related proteins
is possible, thereby allowing to selectively interfere with or
manipulate single family members and investigate the
consequences in cultured cells or in vertebrate animals; such
selections have now been moved to high-throughput technologies
(J. Schaefer and A.P., unpublished). Similar approaches have also
been used in cell culture to interfere specifically with functions of
only particular members from large families of similar proteins
(Amstutz et al., 2005; Kawe et al., 2006; Parizek et al., 2012;
Schweizer et al., 2007), act as a temporal and spatial sensor of
protein conformation and function (Kummer et al., 2012), or to
interfere specifically with a subset of protein–protein interactions
of a given protein (Yeh et al., 2013).
Here we have shown that the GFP-DARPin can be used in
protein degradation assays (Fig. 4), in assays similar to the ones
previously used with the GFP nanobody (Caussinus et al., 2012).
We believe that none of the two binders is a priori a superior
choice in such a degradation experiment which depends to a large
extent on, e.g. accessibility of the binder to the fusion protein and/
or amino acid sequence and properties of the target. Therefore a
quantitative comparison between DARPin and nanobody based
protein degradations is meaningless. Indeed, a broad panel of
GFP-fusion proteins is being tested in our and other labs; we have
previously observed that not all GFP-fusion proteins are easily
accessible for degradation using the GFP nanobody (also see
Caussinus et al., 2013 for a detailed discussion) and we expect the
same with the anti-GFP DARPins. More importantly, however,
the DARPin selection procedure is a fully streamlined in vitro
approach and specific binders can be selected against new targets
in a matter of weeks. In any case, having additional highly
specific GFP and mCherry binders at hand now should increase
the options of designing experiments, e.g. for protein degradation.
We expect that the DARPins described here will provide useful
tools in different fields of biology. Having binders to different
fluorescent proteins in hand will certainly allow additional
biological approaches to be developed and increase their
modularity. For example, a bipartite DARPin molecule can
easily be engineered in many desired geometries and
stoichiometries (e.g. Stefan et al., 2011), thereby bringing GFP-
and mCherry-fusion molecules into close proximity in a
predetermined orientation, which would allow the assembly of
novel protein complexes with predetermined geometry.
These DARPins can be used in any system where GFP or
mCherry can be expressed. Indeed, we show for the first time that
we can use them in living zebrafish embryos and change the
intracellular location of a GFP-tagged protein in that system. We
are convinced that such protein binders can be used in virtually all
biological systems. Together with new genome editing tools,
including TALEN or CRISPR/Cas9 (Hsu et al., 2014), one can
envision to influence the location and thus signaling of proteins
also in non-classical model systems. The genome of such systems
could, for example, be engineered to express specific GFP fusion
proteins and these could later be observed in real time, in the
absence and the presence of protein binders that re-localize or
degrade these fusion proteins.
MATERIALS AND METHODS
All animal experiments conform to the relevant institutional and
regulatory standards of the Swiss Academy of Sciences.
Ribosome display selection of GFP- and mCherry-binding
DARPins
DARPin N3C and N2C libraries (Binz et al., 2004) were used and
ribosome display (RD) selections were performed as described (Dreier
and Plu¨ckthun, 2011). Green Fluorescent Protein (GFP) or mCherry,
containing a C-terminal His-tag and an N-terminal avi-tag for in-vivo
biotinylation during expression, were used as targets. Four rounds of RD
with increasing stringency were carried out in solution with pull-down of
the ternary complexes using streptavidin-coated magnetic beads. In the
fourth round an off-rate selection with 300-fold excess of unbiotinylated
GFP or mCherry over biotinylated target was performed. After the fourth
round the enriched DNA pools were subcloned into the expression vector
pQIq (Simon et al., 2012). For each selection, 192 single clones of each
pool were screened by crude extract ELISA as described previously (Binz
et al., 2004; Zahnd et al., 2006). All single clones were also screened for
binding to superfolder GFP (sfGFP). The nomenclature of the binders is
as follows: the first number indicates the N2C or N3C library,
respectively, the letters G or m indicate a DARPin specific for GFP or
mCherry, respectively, and the last two- to three-digit number is a
continuous numbering of the 192 clones that were screened. 3G86.1 and
3G86.32 come from the same initial clone that turned out to be a double
transformant; single transformants were obtained by plasmid extraction
and retransformation.
Protein expression and purification
The pQIq vectors containing the DARPin genes were used directly for
larger scale expressions. E. coli XL1 blue was transformed. From a single
colony an overnight culture was grown in 2YT medium with 100 mg/ml
ampicillin and 1% glucose. This was used to inoculate 2YT medium
containing 100 mg/ml ampicillin to an OD600 of 0.1 in a shake flask. This
culture was grown at 37 C˚ to an OD600 of 0.6–0.8 and then induced by
addition of 500 mM IPTG. Five hours after induction cells were harvested
by centrifugation (4000 g, 10 min) and resuspended in TBS_W (50 mM
Tris-HCl pH 7.4, 400 mM NaCl, 20 mM imidazole, 10% glycerol). Cells
were lysed by passage through a French press and cell debris was pelleted
by centrifugation (20,000 g, 30 min). Supernatants were then applied to
Ni-NTA superflow resin columns (Qiagen) and washed with 30 column
volumes of TBS_W. Proteins were eluted with TBS_E (same as TBS_W
but containing 250 mM imidazole).
ELISA assay
96-well Maxisorp plates (Nunc) were coated with 100 ml NeutrAvidin
(33 nM in PBS, Thermo Scientific) for 1 h and then blocked with 200 ml
PBS-TB (PBS with 0.1% Tween-20 and 0.2% bovine serum albumin).
After washing (three times with 300 ml PBS-T) wells were coated with
100 ml in-vivo biotinylated autofluorescent proteins (200 nM in PBS-
TB), and control wells were incubated with PBS-TB only. After washing,
IMAC purified DARPins were applied (100 ml, 200 nM in PBS-TB).
DARPins were detected via an anti-RGS-His6 antibody (Qiagen, 1:5000
in PBS-TB), an anti-mouse-IgG conjugated to alkaline phosphatase
(Pierce, 1:10,000 in PBS-TB) and p-nitrophenylphosphate (3 mM in
50 mM NaHCO3, 50 mM MgCl2). The first and second antibody was
each applied for 1 h with three washing steps after incubation. After
incubation with substrate for about 1 h at room temperature the
absorbance at 405 nm was measured on a Tecan M1000 plate reader.
All values were determined in duplicates. Note that 3m160 shows a very
weak binding signal with mRuby2 in this ELISA, but this phenomenon is
also seen with other DARPins, including the control DARPin off7, and
thus likely an unspecific interaction with mRuby2 (Fig. 1A).
Size exclusion chromatography (SEC)
DARPins after IMAC purification were analyzed at a concentration of
10 mM on a Superdex 75 5/150 GL column (GE Healthcare) using an
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A¨kta Micro system (GE Healthcare) with PBS as the running buffer.
Absorbance at 280 nm was recorded; for analysis the maximal
absorbance value was normalized to 1 to compensate for different
extinction coefficients of the DARPins. 2m22 and 2m74 which had very
low extinction coefficients at 280 nm were analysed by absorbance at
230 nm. b-amylase (200 kDa), bovine serum albumin (66 kDa), carbonic
anhydrase (29 kDa) and cytochrome c (12.4 kDa) were used as molecular
mass standards.
Fluorescence anisotropy assay (FA)
The whole assay was performed at room temperature in PBS (pH 7.4)
containing 0.03% bovine serum albumin (BSA) (unless stated otherwise)
in black non-binding 96-well plates (Greiner). Constant amounts of
autofluorescent proteins (GFP, sfGFP or mCherry) at a concentration
below the expected KD were titrated with a dilution series of DARPins
(four replicates). The mixtures were left to equilibrate for 1 h. FA was
measured on a Tecan Safire II plate reader. Mean anisotropy values (a
dimensionless quantity) were normalized by subtraction of the mean
anisotropy value of the sample containing the lowest DARPin
concentration. These normalized mean values were plotted against the
DARPin concentration. The KD was determined by fitting the data to a
simple 1:1 binding model using SigmaPlot. For the epitope-binning
assays, all measurements were carried out with DARPin concentrations
high enough that all targets were completely saturated (2 mM), GFP was
used at 50 nM. GFP was incubated either without any DARPin, with one
DARPin or with two DARPins. Anisotropy was measured on a Tecan
Safire II plate reader; all samples were prepared in duplicates.
Surface plasmon resonance (SPR)
All SPR experiments were performed on a ProteOn XPR36 instrument on
a NLC chip, using PBS containing 0.005% Tween-20 as running buffer.
In-vivo biotinylated GFP was used as ligand. For kinetic measurements a
kinetic titration approach (Karlsson et al., 2006) was used, since no
regeneration condition could be found, that (i) removed all bound
DARPins from the surface and (ii) left the immobilized GFP intact. In
short, after immobilization of GFP in two ligand channels (replicates)
five consecutive injections of the same DARPin with increasing
concentrations were run in the same analyte channel. Data were
referenced (interspot and buffer control) and injections were
concatenated in the ProteOn manager software. These final datasets
were then exported to a .txt-file and imported to the BiaEvaluation
software, where they were fitted to a kinetic titration model described
(Karlsson et al., 2006). This model also contained a term for baseline drift
(which was set to 0) and a mass transfer constant kt, which was manually
set to 1020, which is several orders of magnitudes above ka (ca. 10
14-
fold), since there was no evidence of mass transfer.
For the epitope binning experiments, GFP was immobilized in one
ligand channel, then 1 mM of one DARPin was injected in all analyte
channels. A second injection was performed as soon as the instrument
was ready, at which point 1 mM of each GFP binding DARPin was
injected in one of the analyte channels. Data were referenced in the
ProteOn manager software and inspected manually.
Cell culture
HeLa S3 cells were cultured in DMEM GlutaMAX (GIBCO) containing
10% FBS (GIBCO). Sub-confluent cells were split 1:10 into chamber
slides (Ibidi). The next day, cells were transfected with 0.2 mg of
the corresponding DNA using TransIT (Mirus), according to the
manufacturer’s protocol. 24 hours later, cells were washed with PBS
and fixed with 4% formaldehyde in PBS for 10 minutes. Cells were
washed again twice with PBS and imaged using a confocal microscope,
Leica SP5. Images were processed using ImageJ.
Molecular biology
All DARPin fusion proteins were generated in pcDNA3 plasmids using
the CMV promoter. Genetic constructions were carried out using
restriction-free cloning (Bryksin and Matsumura, 2010) using Phusion
polymerase (NEB). Primer sequences are available upon request.
Drosophila melanogaster
Flies were grown on standard fly medium supplemented with yeast.
NSlmb-3G86.32 was cloned in pUAS_attB to generate transgenic flies
using the zh-86Fb landing platform (Bischof et al., 2007). Beside this
strain, the following fly strains were used in this study: en-Gal4
(Bloomington Drosophila Stock Center (BDSC)), tub-Gal4 (BDSC),
UAS_mCherry-NLS (Caussinus et al., 2008), ubiHis2Av::EYFP (Rebollo
and Gonza´lez, 2004), sqhAX3; sqhSqh::GFP (Royou et al., 2004) and
Gal4332.3 (BDSC).
Danio rerio
Zebrafish were maintained at standard conditions (Westerfield, 1993).
Fertilized eggs of wild type embryos (ABC) were injected at the 1-cell
stage with 25 ng/ml of respective plasmid DNA. Plasmid h2afx:EGFP-
Rab5c (Clark et al., 2011) was used to label the Rab5c vesicles. At ,36
hpf embryos with transient expression of fluorescent markers were
chosen and mounted in a 35 mm glass bottom Petri dish (0.17 mm,
MatTek), using 0.7% low melting agarose (Sigma) containing 0.08%
tricaine and 0.003% PTU. A Leica TCS SP5 confocal microscope with a
406water objective was used for imaging.
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